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Hereditary hemorrhagic telangiectasia (HHT) is a vascular dysplasia characterized by
telangiectases and arteriovenous malformations (AVMs) in particular locations described
in consensus clinical diagnostic criteria published in 2000. Two genes in the transforming
growth factor-beta (TGF-β) signaling pathway, ENG and ACVRL1, were discovered almost
two decades ago, and mutations in these genes have been reported to cause up to
85% of HHT. In our experience, approximately 96% of individuals with HHT have a
mutation in these two genes, when published (Curaçao) diagnostic criteria for HHT
are strictly applied. More recently, two additional genes in the same pathway, SMAD4
and GDF2, have been identiﬁed in a much smaller number of patients with a similar
or overlapping phenotype to HHT. Yet families still exist with compelling evidence of a
hereditary telangiectasia disorder, but no identiﬁable mutation in a known gene. Recent
availability of whole exome and genome testing has created new opportunities to facilitate
gene discovery, identify geneticmodiﬁers to explain clinical variability, and potentially deﬁne
an increased spectrum of hereditary telangiectasia disorders. An expanded approach to
molecular diagnostics for inherited telangiectasia disorders that incorporates a multi-gene
next generation sequencing (NGS) HHT panel is proposed.
Keywords: HHT, molecular diagnostics, genetics, telangiectasia, arteriovenous malformation, Rendu-Osler-Weber
INTRODUCTION
Hereditary hemorrhagic telangiectasia (HHT) or Rendu-Osler-
Weber syndrome is an autosomal-dominantly inherited vascular
malformation syndrome characterized by telangiectases and arte-
riovenous malformations (AVMs) that occurs in 1 in 10,000
individuals (Marchuk et al., 1998). Hallmark features are recur-
rent epistaxis due to telangiectases of the nasal mucosa; dermal,
oral, and gastrointestinal telangiectases; solid-organ AVMs, par-
ticularly of the lungs, liver, and brain; and a family history of
the same. Presentation with three of these criteria is considered
diagnostic for HHT (Shovlin et al., 2000). The dermal telangiec-
tases are generally pinpoint to pinhead sized, very speciﬁcally
concentrated on the hands, face, and lips, and not diffuse. A
typical adult with HHT might have a dozen oral/dermal telang-
iectases spread between these locations, usually observed only
by focused examination. Cutaneous lesions on the limbs and
trunk are not characteristic. Epistaxis most often becomes grad-
ually worse, is sometimes stable for long periods of time, but
it is essentially unreported for it to spontaneously resolve once
started.
Hereditary hemorrhagic telangiectasia exhibits age-related
penetrance and the average age of onset varies with manifestation.
Approximately 50% of affected individuals have nosebleeds by age
ten years and 80–90% by age 21 years. At least 95% eventually
develop recurrent nosebleeds. But severity varies tremendously
and includes nosebleeds from 3 to 6 times per year of less than
a minute in duration, to multiple gushing nosebleeds daily. The
percentage of individuals with telangiectases of the hands, lips,
face, and oral cavity approaches 100% by later adulthood, but
are often not apparent until the second or third decade of life
(Plauchu et al., 1989 and Porteous et al., 1992). Cerebral and pul-
monary AVMs, however, are largely congenital lesions (Morgan
et al., 2002; McDonald et al., 2011b). Signiﬁcant intra-familial as
well as inter-familial variability is the rule; both in terms of the
site and number of telangiectases or AVMs, and severity of related
symptoms (McDonald et al., 2011b).
In the last two decades multiple genes associated with HHT
have been identiﬁed and molecular diagnostics has become a
routine aspect of medical management, genetic counseling and
risk assessment in families with this disorder. This review will
summarize current knowledge regarding the genetics of HHT,
the phenotypes in molecular subgroups of patients, and the sta-
tus of molecular diagnostics for HHT. Implications of recent
discoveries in genetics and advancements in molecular diag-
nosis on the clinical deﬁnition and diagnosis of HHT will be
discussed.
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KNOWN GENES AND PATHWAYS
Hereditary hemorrhagic telangiectasia is a genetically heteroge-
neous disorder caused by mutations in one of multiple genes
in the transforming growth factor-beta (TGF-β) signaling path-
way that regulates cell proliferation, differentiation, apoptosis,
and migration. Endoglin (ENG, chromosome 9q34), activin A
receptor type II-like 1 (ACVRL1/ALK1, chromosome 12q13), and
SMAD4 (chromosome 18q21) mutations cause HHT1 (OMIM
187300),HHT2 (OMIM600376), and the combined Juvenile Poly-
posis/HHT (JP/HHT) syndrome (OMIM 175050), respectively
(Shovlin et al., 1994; Johnson et al., 1996; Gallione et al., 2004).
ENG was identiﬁed as an HHT causative gene 20 years ago (McAl-
lister et al., 1994) followed byACVRL1 in Johnson et al. (1996) and
SMAD4 Gallione et al. (2004). ENG and ACVRL1 encode TGF-β
pathway receptor proteins that are involved in the phosphoryla-
tion of Smad proteins and regulation of downstream signaling
(Figure 1).
Endoglin andACVRL1mutations are detected in approximately
85% of cases submitted to clinical molecular genetics laborato-
ries for clinical suspicion of HHT. Over 750 pathogenic ENG and
ACVRL1 mutations have been described to date (HHT muta-
tion databases1, 2). The HHT mutation database3 is the most
comprehensive database for endoglin and ACVRL1 mutations
described in HHT cases and is representative of a collection
of mutations described in the literature as well as submissions
from clinicians and researchers from around the world. Phe-
notype information, when available, is listed along with the
variant classiﬁcation (i.e., pathogenic, variant of uncertain sig-
niﬁcance, or benign) and reference for each genetic variation.
Most mutations in ENG and ACVRL1, which together account
for roughly equal percentages of the disorder (Bayrak-Toydemir
et al., 2004), lead to the underproduction of their respective pro-
teins and excessive abnormal angiogenesis (Abdalla and Letarte,
2006). The analysis of endoglin and ALK1 protein levels in
affected HHT patients strongly supports haploinsufﬁciency and
the associated reduced levels of functional protein as the underly-
ing cause of HHT1 and HHT2, respectively. Missense mutations
are the most common mutation type observed in ENG and
ACVRL1, and mutations have been identiﬁed in all exons of
both genes. Although less common than missense mutations
in ENG and ACVRL1, the proportion of mutations causing a
truncating frameshift or stop codon (i.e., indels and non-sense
mutations) are more frequent in ENG than in ACVRL1 (Lesca
et al., 2004 3).
No common mutation “hotspots” have been observed in either
gene and mutations have been observed across all coding regions.
However, many ENG mutations have been identiﬁed in the extra-
cellular region of the protein, the largest part of the protein
(Abdalla and Letarte, 2006). Large deletions or duplications of one
or more exons account for 6–10% of all ENG and ACVRL1 muta-
tions (McDonald et al., 2011a). Recently, mutations in the 5′UTR
region of ENG (c.−9G>A and c.−127C> T) were also shown to
causeHHT in several patients, indicating the need for the inclusion
1http://www.arup.utah.edu/database/ACVRL1/ACVRL1_welcome.php
2http://www.arup.utah.edu/database/ENG/ENG_welcome.php
3http://www.arup.utah.edu/database/hht/
FIGURE 1 | Hereditary hemorrhagic telangiectasia is a genetically
heterogeneous disorder caused by mutations in several genes in the
TGF-β/BMP signaling pathway. BMP9 binds to speciﬁc type I (R-I; namely
ALK1) and type II (R-II) cell surface receptors that exhibit serine/threonine
kinase activity, as well as to the auxiliary receptor endoglin. Upon ligand
binding, the R-II transphosphorylates ALK1 (R-I), which then propagates the
signal by phosphorylating receptor-regulated Smads (R-Smads) Smad1/5/8.
Once phosphorylated, R-Smads form heteromeric complexes with Smad4
and translocate into the nucleus where they regulate transcriptional activity
of target genes, including Id1. Endoglin, ALK1, BMP9, and Smad4 proteins
are encoded by ENG, ACVRL1, GDF2, and SMAD4, whose pathogenic
mutations give rise to HHT and JP/HHT, respectively. This ﬁgure was
adapted from (Fernández-L et al., 2006).
of the ENG 5′UTR region in routine molecular diagnostic testing
for HHT (Damjanovich et al., 2011).
Denovomutations andmosaicism involving these two genes are
rare, but have both been reported. Two patients with no family his-
tory of HHT were shown to be mosaic for a mutation in ACVRL1
and ENG, respectively (Best et al., 2011). In addition, three cases
have been conﬁrmed to represent de novo mutations in a series
of 126 patients known or suspected to have HHT (Gedge et al.,
2007). Also a large endoglin deletion was shown to convert from
an exon 4–7 deletion to a de novo exon 3 deletion in one generation
within a family. This was likely due to non-homologous end-
joining (NHEJ) repair of a common breakpoint in ENG intron
3 (Wooderchak et al., 2010b). This ﬁnding has implications for
molecular diagnostics since targeted family speciﬁcmutation anal-
ysis for exon deletions could have led to the misdiagnosis of some
affected family members.
A SMAD4 mutation is detected in less than 2% of cases submit-
ted for clinical suspicion of HHT (Gallione et al., 2006; Lesca et al.,
2006; Prigoda et al., 2006). Nearly 100 SMAD4 missense, non-
sense, frameshift, splice site, and large deletion mutations have
been described throughout the gene (Wooderchak et al., 2010a).
Initial reports of the combined JP/HHT syndrome suggested that
mutations in the MH2 domain were in particular responsible for
the HHT phenotype. It is now clear that the spectrum of SMAD4
mutations in patients or families described as having Juvenile
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Polyposis Syndrome (JPS) alone are almost identical to those with
JP/HHT combined (Gallione et al., 2010). Thus all patients with a
mutation in the SMAD4 gene should be considered at risk for the
features of both JPS and HHT.
Approximately 15% of individuals suspected by their physician
to have HHT have no mutation in ENG, ACVRL1, or SMAD4.
Determining the genetic basis of HHT manifestations in patients
who do not have a mutation in one these three genes has remained
a great challenge for nearly a decade. Linkage analysis identiﬁed
two additional HHT loci at chromosome 5q31 (Cole et al., 2005)
and chromosome 7p14 (Bayrak-Toydemir et al., 2006b), but the
genes still remain unknown. One patient with signs of HHT and
pulmonary arterial hypertension was found to have a non-sense
mutation in the bone morphogenetic protein receptor, type II
gene, BMPR2 (Rigelsky et al., 2008).
Recently, exome sequencing was used to identify missense
mutations in the bone morphogenetic 9 (BMP9) gene (GDF2,
chromosome 10q11) in two unrelated individuals suspected to
have HHT who previously tested negative for ENG, ACVRL1,
and SMAD4. A third case was identiﬁed by Sanger sequencing
of GDF2 in additional such individuals (Wooderchak-Donahue
et al., 2013). These patients had epistaxis, telangiectasia, and some
reported family history of symptoms associated with HHT- pri-
marily epistaxis (OMIM 615506; Wooderchak-Donahue et al.,
2013). BMP9 exerts its functional effects by binding to speciﬁc
endothelial cell surface receptors, namely the auxiliary receptor
endoglin and the serine-threonine kinase, ALK1, both members
of the highly conserved TGF-β superfamily. The BMP9-dependent
activation of ALK1 leads to the phosphorylation of Smad1, Smad5,
and Smad8. The resulting phospho-Smad proteins associate with
Smad4 to form a Smad complex that translocates to the nucleus
to regulate gene expression in human microvascular endothelial
cells (Figure 1, adapted from Fernández-L et al., 2006). The overall
contribution of BMP9 mutations for HHT is estimated to be<1%
(Wooderchak-Donahue et al., 2013).
GENOTYPE-PHENOTYPE CORRELATIONS
The common, classic features of HHT: mucocutaneous telang-
iectasia in similar locations (cluster on lips, mouth, hands, and
intestines), epistaxis resulting from nasal telangiectases, and pul-
monary, cerebral and hepatic AVMs, are all found in HHT1,
HHT2, and JP/HHT. However, the rate of solid organ AVMs is
noted to be different between the subtypes. In particular, pul-
monary and cerebral AVMs have been shown to be somewhat
more common in patients with HHT1 than with HHT2; on the
other hand, hepatic manifestations of HHT are more common in
patients with HHT2 than HHT1 (Bayrak-Toydemir et al., 2006a;
Wain et al., 2014). The rate of AVMs in solid organs is less well
known in JP/HHT patients, but the small series reported to date
suggest that it is not less than in HHT1 and HHT2 (Gallione et al.,
2010; Wain et al., 2014).
Pulmonary arterial hypertension (PAH) is a rare manifesta-
tion of HHT. It has been reported mostly in HHT2, but has also
been reported in HHT1 (Trembath et al., 2001; Soubrier et al.,
2013). One individual with both PAH and signiﬁcant clinical sus-
picion for HHT was found to have a clearly deleterious mutation
in BMPR2 (Rigelsky et al., 2008).
The phenotype associatedwith amutation inGDF2 is currently
ill-deﬁned. Pathogenic variants in GDF2 have been described in
only three individuals who had been suspected by their referring
doctor to haveHHT.But reviewof available clinical details revealed
that in one case some of the dermal telangiectases were larger than
the pinpoint-pinhead size lesions that typify HHT – more like
those described in patients with Capillary Malformation- AVM
Disorder (Revencu et al., 2013). Liver imaging in this same patient
was suggestive of hepatic vascular ﬁndings seen in HHT patients.
However, the individual had also been diagnosed with hepatopul-
monary syndrome and the cause of her hepatic issues is not clear.
In another case, the telangiectases were more numerous and not
limited to the hands, mouth, and face (∼80 on one arm), as is
typical of HHT (Wooderchak-Donahue et al., 2013).
Although the above described clinical variation between HHT
molecular subtypes has been shown, this is not the case for dif-
ferent mutations within the same gene. Data suggest that most
disease-causing mutations in ACVRL1, ENG, and SMAD4 are
null alleles that result in haploinsufﬁciency. One mutation (ENG
c.−9G > A) has been seen in multiple affected individuals, one
who was homozygous for this mutation, and expression studies
showed decreased protein levels, suggesting a hypomorphic allele
(Damjanovich et al., 2011). But as a rule, there does not appear
to be phenotype variation dependent on the location or mutation
type within these genes (Berg et al., 1997; Pece et al., 1997; Gallione
et al., 1998).
GENETIC MODIFIERS
Hereditary hemorrhagic telangiectasia has signiﬁcant phenotypic
variability, wherein the number and location of telangiectases and
AVMs vary widely between individuals even within the same fam-
ily. The genetic heterogeneity of HHTdoesnot explain the variable
clinical symptoms and manifestations routinely seen within fami-
lies. The signiﬁcant intra-familial variation in phenotype suggests
effects of genetic modiﬁers on the HHT phenotype. Two genes,
PTPN14 and ADAM17, were recently identiﬁed as genetic mod-
iﬁers of angiogenesis and HHT (Benzinou et al., 2012; Kawasaki
et al., 2014). PTPN14 variants have been shown to inﬂuence the
clinical severity of HHT by being associated with the development
of pulmonary AVMs in HHT patients (Benzinou et al., 2012).
ADAM17 variants have been associated with the presence of pul-
monary AVMs in HHT1 but not HHT2 and can potentiate a
TGF-β regulated vascular disease. Additional, yet undiscovered
genetic modiﬁers may also play a role in the development of
vascular lesions seen in HHT.
MOLECULAR DIAGNOSTICS
MEDICAL INDICATIONS
Molecular genetic testing to establish the molecular subtype of
HHT is recommended when HHT is diagnosed or suspected on
clinical grounds. Whether or not the family has a mutation in
SMAD4, in particular, changes clinical management due to the
associated risk of gastrointestinal polyps and malignancy not asso-
ciated with mutations in other HHT genes. While mutations in
SMAD4 cause only a small percentage (∼2%) of all HHT (Gal-
lione et al., 2006; Lesca et al., 2006; Prigoda et al., 2006), the
medical management considerations for the resulting JP/HHT
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Syndrome are such that ruling out a mutation in this gene is clini-
cally relevant. In practice a SMAD4 mutation is usually“ruled out”
in an HHT family proband by the detection of a disease causing
ACVRL1 or ENG mutation, rather than “ruled in” by analysis of
the SMAD4 gene itself.
Secondly, if a pathogenic gene mutation is identiﬁed in an
affected family proband, early diagnostic testing is then available
as recommended for at-risk family members. In contrast to many
hereditary disorders, diagnostic genetic testing for HHT is recom-
mended early in life for ﬁrst degree relatives of affected individuals,
even when asymptomatic or minimally symptomatic. The diag-
nosis of HHT can rarely be made, and can never be ruled out,
based purely on medical history and physical examination in the
ﬁrst decade of life. This is because the average age of epistaxis
onset is 12 years, and multiple mucocutaneous telangiectases are
often not apparent until the third decade (Assar, 1991; Porteous
et al., 1992); yet solid organ AVMs are usually present from birth.
Because serious complications of pulmonary and cerebral AVMs
can occur without warning at an early age, and most are pre-
ventable, (Morgan et al., 2002; Mei-Zahav et al., 2006), screening
for pulmonary and cerebral AVMS is recommended in all affected
children (Al-Saleh et al., 2009; Faughnan et al., 2011). HHT is a
disorder in which recommended medical management is changed
by making an early diagnosis.
HHT MOLECULAR DIAGNOSTICS TO DATE
The genetic complexity and number of mutations described in
HHT have made it challenging to determine an efﬁcacious algo-
rithm for diagnostic testing. Since molecular diagnostic testing
became available a decade ago, the norm has been an algorithm
that involvedSanger sequencing for pointmutations andmultiplex
ligation-dependent probe ampliﬁcation (MLPA) for the detection
of large deletions and duplications in ENG,ACVRL1, and SMAD4.
The results of 383 consecutive samples submitted toARUPLabora-
tories (2014a,b) forHHTmolecular testing between 2007 and 2009
were reviewed and led our group to propose a testing algorithm in
which theENG andACVRL1 geneswere simultaneously sequenced
and analyzed for large deletions and duplications as the initial
analysis. This approach accounted for the fact that the majority
of these 383 family probands had required both genes to be fully
analyzed for optimal mutation detection and accurate interpreta-
tion of results. When a uniquemissensemutationwas (frequently)
detected in either ACVRL1 or ENG gene, it was helpful to know
that no deletion/duplicationwas detected in the same gene; and no
mutation by either sequencing or deletion/duplication analysis in
the other gene. In addition, since ACVRL1 and ENG each account
for slightly less than half of all cases, the need to test the other gene
in a particular case was the rule. In our experience, when efﬁciency
(related to cost), accuracy and turnaround time were considered,
a protocol by which ENG and ACVRL1 were simultaneously ana-
lyzed, with reﬂex to SMAD4 if both were negative, has seemed the
most efﬁcacious algorithm for molecular diagnostics for most of
the last decade (McDonald et al., 2009, 2011b).
CLINICAL SENSITIVITY
To date, reports of the detection rate for a mutation in ENG
and ACVRL1 in HHT have come from laboratories, which receive
samples from clinicians with awide range of expertise with regards
to recognizing clinical manifestations of HHT (Richards-Yutz
et al., 2010; McDonald et al., 2011b). In general, a mutation is
detected in either ENG or ACVRL1 in approximately 75% of cases
in which the ordering physician reports the individual to have
HHT. But Richards-Yutz et al. (2010) reported that the muta-
tion detection rate for ENG and ACVRL1 ranged from 85% if
the ordering physician speciﬁcally reported the patient to have
all four Curaçao diagnostic criteria (Epistaxis, Telangiectases,
AVM, Family History); to ∼40% if three diagnostic criteria were
reported, and the three criteria were speciﬁcally telangiectasia,
AVM and family history. It is clear that all clinical manifesta-
tions and all physician assessments are not equally predictive of
having a mutation in ENG or ACVRL1, the two common genes
for HHT.
Our group forms the core of the University of Utah HHT
Center, which has provided clinical diagnosis and medical man-
agement for this disorder since 1995. We recently reviewed our
patient database for individuals who upon physical examination,
medical history and family history met clinical diagnostic cri-
teria based on a strict application of the Curaçao criteria (IRB
00039582). This meant three or more of the following: multiple
mucocutaneous telangiectases in characteristic locations; recurrent
and ongoing epistaxis; pulmonary, cerebral, hepatic, and/or spinal
AVM(s); and a ﬁrst degree relative who meets diagnostic crite-
ria. 95.7% of such individuals/family probands had a mutation in
ENG or ACVRL1 that was known or suspected to be pathogenic;
1.4% in SMAD4. (McDonald, unpublished data). It is of note that
based onmutation prediction programs and family co-segregation
studies performed for uncertain variants in these genes over time,
it is our experience that most missense mutations initially inter-
preted as variants of uncertain signiﬁcance due to insufﬁcient of
evidence of causation are actually pathogenic (Bayrak-Toydemir
et al., 2008).
Finally, the inclusion of the ENG 5′UTR region in HHT
molecular diagnostic testing has increased the overall clinical sen-
sitivity (Damjanovich et al., 2011; ARUP, unpublished results).
Deep intronic ENG and ACVRL1 mutations can cause HHT by
causing splicing defects. In fact, we hypothesize that most of
the ∼3% of patients with HHT according to Curaçao criteria
who are not found to have a mutation in ACVRL1, ENG, or
SMAD4, have an undetected deep intronic mutation in ACVRL1
or ENG.
IMPORTANT RECENT ADVANCES IN MOLECULAR GENETIC ANALYSIS
The last several years have seen the transition of whole exome
and whole genome sequencing (e.g., next generation sequenc-
ing (NGS) or massively parallel sequencing) from use only in
research, to use in clinical diagnostics. As is often the case with
technology, this transition to wider use is largely related to dras-
tic reductions in cost. NGS allows for many human genes to be
sequenced in one orderable test; as opposed to single-gene analysis
by Sanger sequencing which has been the mainstay of molecu-
lar diagnostics for the last several decades. And NGS testing has
been shown to have a higher analytical sensitivity than traditional
Sanger sequencing due to increased potential to detect low level
mosaicism.
Frontiers in Genetics | Genetic Disorders January 2015 | Volume 6 | Article 1 | 4
McDonald et al. HHT genetics in a new era
On the other hand, this new technology still adds cost in most
cases, and can decrease detection rates for mutations in certain
genes. It can also increase turnaround time from weeks to months.
Most concerning to many is the increased complexity and poten-
tial ambiguity of results. The risk of detecting genetic variants of
uncertain clinical signiﬁcance exists for gene sequencing using any
technology. But the chance of detecting a variant of unknown sig-
niﬁcance, with the inherent uncertainty and anxiety this causes
for clinician and patient alike, multiplies relative to how many
genes are sequenced. This must be balanced with the advantages
of testing multiple genes with one assay.
NEW CONSIDERATIONS AND PROPOSED TESTING ALGORITHM
An expanded approach to molecular diagnostics for HHT is
evolving due to the increasing use of NGS in the clinical molec-
ular diagnostic setting, and the discovery in 2013 of pathogenic
mutations in the GDF2 gene in three patients clinically sus-
pected to have HHT. Also, RASA1 gene mutations have been
detected in a small number of patients who had been clinically
suspected to have HHT (Wooderchak-Donahue, unpublished
results). Although the appearance and location of the cutaneous
capillary malformations or telangiectases described in RASA1-
related disorder/Capillary Malformation-AVM Syndrome (CM-
AVM) are distinguishable from those in HHT, there is enough
similarity that making the distinction can be difﬁcult for clini-
cians without speciﬁc expertise in the identiﬁcation of vascular
malformations.
Thus, when the goal is to rule out a mutation in genes associ-
ated with the HHT phenotype, there are now arguably three genes
SMAD4, GDF2, and RASA1, each low yield for a mutation that
might reasonably be considered. Yet, a mutation in ACVRL1 or
ENG is found in approximately 96%of patients whomeet Curaçao
clinical diagnostic criteria when strictly applied.
Given the above considerations, we now choose one of two dif-
ferent molecular diagnostic approaches for a family proband who
presents in our specialty clinic for HHT (Figure 2). If evaluation
based on the targeted medical history, physical examination, and
multi-generation family history suggests:
(1) Classic HHT as deﬁned by the Curaçao criteria; testing of ENG
and ACVRL1 by Sanger Sequencing and deletion/duplication
analysis with reﬂex to SMAD4 if ENG andACVRL1 test results
are negative.
(2) Suspicion for a hereditary telangiectasia syndrome but not
necessarily for classic HHT (e.g., telangiectases with atypical
distribution, lack of epistaxis, lack of solid organ involvement);
a ﬁve gene (ENG, ACVRL1, SMAD4, RASA1, and GDF2) NGS
panel (Table 1) and corresponding array comparative genomic
hybridization (aCGH) for the detection of large deletions and
duplications in the same ﬁve genes.
If a causativemutation is not identiﬁed by the chosen approach,
symptom guided exome sequencing is considered (Figure 2).
CONCLUSION AND FUTURE DIRECTIONS
With the advent of NGS techniques, a new era for gene discovery,
genetic modiﬁer identiﬁcation to explain the clinical variability
seen in HHT, and molecular diagnostics for HHT has begun. The
discovery last year that a mutation in GDF2 can cause a pheno-
type similar to HHT was made possible by exome sequencing. The
addition of this gene to the growing list of genes to be considered
when a patient is suspected to have a hereditary telangiectasia syn-
drome, in turn increases the potential efﬁcacy of a multiple gene
panel test made possible by NGS when deciding on a molecular
diagnostic test.
Additional genes associated with an HHT phenotype will likely
be identiﬁed. By deﬁnition, each will be a small contributor to
the overall incidence of HHT. But additional genes can easily be
added to an HHT NGS panel to increase clinical sensitivity. The
more genes that are identiﬁed, and as the cost and turn-around
time for NGS and complementary aCGH continue to go down
with time, this assay will likely become the method of choice for
the molecular diagnosis of individuals suspected to have HHT
(dashed line, Figure 2). Also, the contribution of deep intronic,
UTR, or promoter variants of one of the known genes (ENG,
ACVRL1, or SMAD4) is still not well known. As the non-coding
and regulatory regions of these genes are better understood, these
FIGURE 2 | Proposed molecular testing algorithm for HHT based on the
suspected clinical diagnosis.The testing algorithm for classic HHT is shown
on the left. An algorithm for patients suspected to have HHT or an HHT-like
phenotype (right) depicts the use of a ﬁve gene HHT next generation sequen-
cing panel and aCGH. The dashed line indicates a streamlined future diagnostic
algorithm for HHT patients as NGS costs and turn-around times are reduced.
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Table 1 | Hereditary hemorrhagic telangiectasia next generation sequencing panel genes.
Gene name Chromosomal
locus
Protein name Disease Reference
sequence
Exons
ENG 9q33-q34.1 Endoglin HHT1 NM_001114753 14
ACVRL1 12q11-q14 Activin A receptor type II-like 1
(ALK1)
HHT2 NM_000020 10
SMAD4 18q21.1 SMAD, mothers against DPP
homolog 4 (Drosophila) MADH4
JPS/HHT NM_005359 12
GDF2/BMP9 10q11.22 growth differentiation factor 2 HHT-like NM_016204 2
RASA1 5q13.3 RAS p21 protein activator
(GTPase activating protein) 1
RASA1-related disorders CM/AVM
Parkes Weber Syndrome
NM_002890 25
This ﬁve gene HHT panel is available for clinical testing at ARUP Laboratories. HHT, hereditary hemorrhagic telangiectasia; JPS, juvenile polyposis syndrome.
regions can also be included in diagnostic testing to increase the
overall clinical sensitivity of HHT molecular diagnostics.
Importantly, HHT patients who had molecular genetic testing
in the past, in whom no pathogenic mutation was detected, should
be considered at the time of follow-up consultation for retesting or
additional testing using current protocols and techniques. Molec-
ular diagnostics 10 years ago involved only sequencing of coding
regions of ENG and ACVRL1. Large deletions and duplications in
these genes would have been missed as would mutations in the
more recently discovered genes associated with an HHT pheno-
type. Also, mutations in the UTR region of ENG would not have
been detected.
It is increasingly apparent that vascular lesions in other inher-
ited vascular malformation syndromes often harbor a somatic
second genetic hit mutation (Akers et al., 2009; Limaye et al., 2009;
Amyere et al., 2013; Revencu et al., 2013). Biallelic germline and
somatic mutations were identiﬁed in cerebral cavernous malfor-
mations (CCMs) in all three forms of inherited CCM, suggesting
that the formation of these lesions requires complete loss of func-
tion of a CCM gene (Akers et al., 2009). A somatic second hit
mutation was also identiﬁed in tissue from a capillary malforma-
tion in a patient with a germline RASA1 mutation (Revencu et al.,
2013). In addition, inherited venous malformations caused by
GLMN andTIE2 mutations were also shown to follow the somatic
second hit model (Limaye et al., 2009; Amyere et al., 2013). It
will be interesting to determine whether telangiectasias and AVMs
from HHT patients also have a somatic second hit mutation. This
may help explain the presence of multiple vascular lesions in the
same individual and the variable phenotypes observed in families
who carry the same mutation.
Overall, it has become apparent that the genetics as well as
phenotype of HHT are more complex than known and thus
described when the Curaçao diagnostic criteria for HHT were set
forth (Shovlin et al., 2000). At that time in 2000, only the ENG
and ACVRL1 genes were known to be associated with HHT and
Curaçao clinical diagnostic criteria have stood the test of time
for describing the syndromes caused by mutations in these two
genes. Since then, however, two additional genes have been dis-
covered,mutations that cause a hereditary telangiectasia syndrome
which does not clearly ﬁt this deﬁnition of HHT. When our group
reported last year that mutations in GDF2 were found in three
patients with a telangiectasia syndrome, a decision was made to
stop short of labeling it a new type of HHT,because it was not clear
that the dermal telangiectases were typical of HHT as described in
the Curaçao criteria. Also, solid organ AVMs were not conﬁrmed
in any of the three patients, although this could be attributable
to the small number of individuals who had not been thoroughly
evaluated (Wooderchak-Donahue et al., 2013). We have observed
in our clinical center for HHT a number of families that are com-
pelling for having some type of hereditary telangiectasia disorder,
yet do not have a mutation in one of the currently known genes
(ENG, ACVRL1, SMAD4, and GDF2).
Future molecular characterization of families referred for sus-
picion of having HHT will likely require either an expanded
deﬁnition of HHT itself, or an expanded categorization of telang-
iectasia/AVM disorders which includes HHT. But it is clear that
in the near future molecular diagnostic NGS panel assays and
exome and genome sequencing will help elucidate additional
genetic aberrations – both primary causative genes and modi-
ﬁers of phenotype- in HHT patients that have remained elusive
for years.
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